MedTrace Logo

Adjunctive Glycine for Obsessive Compulsive Disorder

NCT00405535 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-12-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether individuals with obsessive compulsive disorder who will take a preparation of the amino acid glycine in addition to their current treatment, may experience improvement in their symptoms.

Conditions

  • Obsessive Compulsive Disorder

Interventions

DRUG

glycine

OTHER

placebo

Sponsors & Collaborators

  • Obsessive Compulsive Foundation

    collaborator OTHER

  • Nathan Kline Institute for Psychiatric Research

    lead OTHER

Principal Investigators

  • William M Greenberg, MD · Nathan Kline Institute for Psychiatric Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405535 on ClinicalTrials.gov